Today: 22 May 2026
Browse Category

NASDAQ:FUTU 12 April 2026 - 22 May 2026

UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

UP Fintech’s Nasdaq-listed shares fell 34.47% to $3.83 in premarket trading after China’s securities regulator said its Tiger Brokers unit, Futu, and Longbridge operated unlicensed cross-border securities businesses for mainland investors. The regulator plans to confiscate illegal gains and impose penalties. UP Fintech is set to report first-quarter results on June 2.
22 May 2026
··
China Closes Retail Access to Overseas Stocks

China Closes Retail Access to Overseas Stocks

China’s securities regulator ordered Tiger Brokers, Futu Securities International, and Longbridge Securities to wind down unapproved cross-border trading for mainland clients, citing illegal operations. Shares of Futu and Tiger parent UP Fintech plunged over 30% in U.S. premarket trading. Existing clients have two years to sell assets and withdraw funds, but cannot make new trades. Authorities plan to confiscate illegal gains.
22 May 2026
·····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 12.04.2026

Futu Holdings (FUTU) rose 10.2% in the past week but trades 13.4% below its January level. Shares closed at $154.50, while analysts estimate intrinsic value at $245.48. The company posted a 92.2% return over 12 months. Valuation models indicate earnings exceed risk costs, supporting long-term growth projections.
12 April 2026
··

Stock Market Today

  • Diageo Shares Show Signs of Turnaround After Steep Decline
    May 22, 2026, 10:08 AM EDT. Diageo (LSE: DGE) shares have rallied about 15% recently after a prolonged 66% drop over four years, signaling a potential turnaround for the owner of Guinness and Smirnoff. A strong third-quarter update with reaffirmed full-year guidance helped restore investor confidence following past profit warnings. Additionally, the U.S. removal of tariffs on Scotch whisky, including the Johnnie Walker brand, boosted prospects in Diageo's largest market. Despite long-term concerns such as changing drinking habits and the impact of GLP-1 drugs, revenue has remained stable around £20 billion. Trading on a price-to-earnings ratio of 18, well below its 10-year average of 24, Diageo shares appear attractively valued. The coming years will test if this rebound marks genuine recovery or volatility-driven gains.

Latest articles

Archer Aviation Rises as Air-Taxi Hopes Return

Archer Aviation Rises as Air-Taxi Hopes Return

22 May 2026
Archer Aviation stock traded at $6.14 in premarket Friday after jumping 5.8% Thursday on heavy volume, as investors watched FAA certification progress for its Midnight eVTOL aircraft. Archer reported a Q1 net loss of $217.7 million and ended March with $1.78 billion in cash. The company expects initial U.S. operations in 2026 under a federal pilot program. S&P 500 and Nasdaq futures were higher before the open.
UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

22 May 2026
UP Fintech’s Nasdaq-listed shares fell 34.47% to $3.83 in premarket trading after China’s securities regulator said its Tiger Brokers unit, Futu, and Longbridge operated unlicensed cross-border securities businesses for mainland investors. The regulator plans to confiscate illegal gains and impose penalties. UP Fintech is set to report first-quarter results on June 2.
Akari Therapeutics Shares Jump As KRAS Cancer News Returns

Akari Therapeutics Shares Jump As KRAS Cancer News Returns

22 May 2026
Akari Therapeutics shares more than doubled in premarket trading Friday after its lead cancer drug showed positive preclinical results in KRAS-mutated pancreatic cancer models and the company announced a $5.5 million private placement. The stock was quoted at $10.15, up from Thursday’s $5.14 close. Akari plans to start Phase 1 human trials of AKTX-101 by mid-2027. The company reported $2.8 million in cash at March 31.
Go toTop